Michael Zinda's most recent trade in Repare Therapeutics Inc was a trade of 5,611 Common Shares done at an average price of $1.1 . Disclosure was reported to the exchange on March 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 1.14 per share. | 12 Mar 2025 | 5,611 | 80,297 | - | 1.1 | 6,397 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 85,000 | 85,000 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 14,000 | 85,908 | - | 0 | Common Shares | |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 4.64 per share. | 28 Mar 2024 | 450 | 72,318 | - | 4.6 | 2,088 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 4.66 per share. | 28 Mar 2024 | 410 | 71,908 | - | 4.7 | 1,911 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 4.62 per share. | 25 Mar 2024 | 450 | 72,768 | - | 4.6 | 2,079 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 4.78 per share. | 25 Mar 2024 | 450 | 73,668 | - | 4.8 | 2,151 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 4.61 per share. | 25 Mar 2024 | 450 | 73,218 | - | 4.6 | 2,075 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 85,000 | 85,000 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 14,000 | 74,118 | - | 0 | Common Shares | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 07 Jun 2023 | 6,404 | 62,987 | - | 12.0 | 77,040 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.02 per share. | 07 Jun 2023 | 2,869 | 60,118 | - | 12.0 | 34,485 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.04 per share. | 06 Jun 2023 | 1,200 | 69,391 | - | 12.0 | 14,448 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 97,100 | 97,100 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 24,550 | 70,591 | - | 0 | Common Shares | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 11.30 per share. | 15 Mar 2022 | 533 | 46,041 | - | 11.3 | 6,023 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 115,000 | 115,000 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 19,590 | 35,260 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 23 Nov 2021 | 19,590 | 36,101 | - | 2.1 | 40,395 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 11,856 | 0 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 23 Nov 2021 | 11,856 | 16,511 | - | 1.6 | 19,408 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 10,473 | 137,993 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.42 per share. | 23 Nov 2021 | 10,473 | 46,574 | - | 2.4 | 25,397 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 23 Nov 2021 | 4,122 | 4,655 | - | 1.6 | 6,748 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 4,122 | 0 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 27.20 per share. | 15 Nov 2021 | 16,100 | 4,433 | - | 27.2 | 437,920 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 27.87 per share. | 15 Nov 2021 | 3,900 | 533 | - | 27.9 | 108,693 | Common Shares |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 33.97 per share. | 16 Aug 2021 | 14,300 | 21,233 | - | 34.0 | 485,771 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 34.45 per share. | 16 Aug 2021 | 700 | 20,533 | - | 34.5 | 24,115 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 32.72 per share. | 17 May 2021 | 12,439 | 37,362 | - | 32.7 | 407,053 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 33.07 per share. | 17 May 2021 | 1,829 | 35,533 | - | 33.1 | 60,493 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 31.65 per share. | 17 May 2021 | 732 | 49,801 | - | 31.6 | 23,165 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 34.24 per share. | 28 Dec 2020 | 14,726 | 70,551 | - | 34.2 | 504,218 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 33.30 per share. | 28 Dec 2020 | 14,539 | 55,690 | - | 33.3 | 484,149 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 34.63 per share. | 28 Dec 2020 | 4,207 | 51,483 | - | 34.6 | 145,688 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 28 Dec 2020 | 950 | 50,533 | - | 35.0 | 33,260 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 34.60 per share. | 28 Dec 2020 | 322 | 70,229 | - | 34.6 | 11,141 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2020 | 48 | 54,850 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 28 Dec 2020 | 48 | 85,277 | - | 2.1 | 99 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 33.36 per share. | 22 Dec 2020 | 39,700 | 85,229 | - | 33.4 | 1,324,392 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 22 Dec 2020 | 25,606 | 126,541 | - | 2.1 | 52,800 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 25,606 | 60,101 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 22 Dec 2020 | 15,706 | 100,935 | - | 1.6 | 25,711 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 15,706 | 13,832 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 33.48 per share. | 22 Dec 2020 | 12,556 | 88,908 | - | 33.5 | 420,375 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.42 per share. | 22 Dec 2020 | 9,488 | 101,464 | - | 2.4 | 23,008 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 9,488 | 148,466 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 22 Dec 2020 | 4,771 | 91,976 | - | 2.1 | 9,838 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 4,771 | 55,330 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 34.26 per share. | 22 Dec 2020 | 3,679 | 85,229 | - | 34.3 | 126,043 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 22 Dec 2020 | 1,976 | 87,205 | - | 1.6 | 3,235 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 1,976 | 11,856 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 22 Dec 2020 | 1,612 | 124,929 | - | 34 | 54,808 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 22 Dec 2020 | 432 | 85,661 | - | 2.1 | 891 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 33.14 per share. | 22 Dec 2020 | 432 | 85,229 | - | 33.1 | 14,316 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 432 | 54,898 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.42 per share. | 21 Dec 2020 | 40,000 | 125,229 | - | 2.4 | 97,000 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 33.08 per share. | 21 Dec 2020 | 40,000 | 85,229 | - | 33.1 | 1,323,200 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 40,000 | 157,954 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 8,321 | 85,707 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.06 per share. | 16 Dec 2020 | 8,321 | 93,550 | - | 2.1 | 17,158 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 34.59 per share. | 16 Dec 2020 | 8,121 | 85,429 | - | 34.6 | 280,905 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 35.17 per share. | 16 Dec 2020 | 8,022 | 86,163 | - | 35.2 | 282,134 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 6,876 | 4,122 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 16 Dec 2020 | 6,876 | 92,105 | - | 1.6 | 11,256 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 2,080 | 29,538 | - | - | Employee Stock Option (right to buy) | |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 16 Dec 2020 | 2,080 | 94,185 | - | 1.6 | 3,405 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 36.01 per share. | 16 Dec 2020 | 934 | 85,229 | - | 36.0 | 33,633 | Common Stock |
| Repare Therapeutics Inc | Michael Zinda | EVP, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 35.10 per share. | 16 Dec 2020 | 200 | 85,229 | - | 35.1 | 7,020 | Common Stock |